TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06182072: ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Sponsor: ProDa BioTech, LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 46 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06182072 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06182072 Rescue Dossier →